Authors: Nishikawa H, Fukunishi S, Asai A, et al.
Published in Anticancer Res 2021
It is estimated that there are more than 10 million NAFLD patients in Japan. 10-20% of NASH patients will progress to liver cirrhosis and 2-3% of them will develop hepatocellular carcinoma per year. In their review, H. Nishikawa et al. (Osaka Medical and Pharmaceutical University, Takatsuki, and Hyogo College of Medicine, Japan) comprehensively...
Authors: Simon TG, Roelstraete B, Sharma R, et al.
Published in Hepatology 2021
Recent studies link NAFLD to an increased incidence of hepatocellular carcinoma (HCC) and extrahepatic cancers. However, prior studies were small or lacked liver histology, which remains the gold standard for staging NAFLD severity. TG Simon et al...
The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study.
Authors: Lee JM, Park YM, Yun JS, et al.
Published in PLoS One. 2020
The authors investigated the association between nonalcoholic fatty liver disease (NAFLD) and gastrointestinal tract cancer in the general population. Retrospective data on individuals aged ≥20 years who received healthcare checkups from January 1, 2009 to December 31, 2009 were analyzed using the National Health Insurance Database in Korea. NAFLD was defined...
Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.
Authors: Malehmir M, Pfister D, Gallage S, Szydlowska M, et al
Published in Nat Med. 2019 Apr;25(4):641-655.
Here, the authors show that platelet number, platelet activation and platelet aggregation are increased in NASH but not in steatosis or insulin resistance. Platelet cargo, platelet adhesion and platelet activation...